ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5

ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5

The proteasome inhibitors (PIs) bortezomib and carfilzomib, which target proteasome 20S subunit beta 5 (PSMB5) in cells, are widely used in multiple myeloma (MM) treatment. In this study, we demonstrated the role of interferon-stimulated 20 kDa exonuclease-like 2 (ISG20L2) in MM PI resistance. Gain-...

Full description

Bibliographic Details
Main Authors: Yan Yang, Yuhan Gao, Jingcao Huang, Zhuang Yang, Hongmei Luo, Fangfang Wang, Juan Xu, Yushan Cui, Hong Ding, Zhimei Lin, Xinyu Zhai, Ying Qu, Li Zhang, Ting Liu, Lingqun Ye, Ting Niu, Yuhuan Zheng
Format: Article
Language:English
Published: American Society for Clinical investigation 2022-10-01
Series:JCI Insight
Subjects:
Hematology
Online Access:https://doi.org/10.1172/jci.insight.157081

Internet

https://doi.org/10.1172/jci.insight.157081

Similar Items